| 2.18 0.09 (4.31%) | 01-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.58 | 1-year : | 3.02 |
| Resists | First : | 2.21 | Second : | 2.58 |
| Pivot price | 1.91  |
|||
| Supports | First : | 1.89 | Second : | 1.7 |
| MAs | MA(5) : | 2.07 |
MA(20) : | 1.88 |
| MA(100) : | 2.03 |
MA(250) : | 1.97 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 82.8 |
D(3) : | 84.6 |
| RSI | RSI(14): 74.5 |
|||
| 52-week | High : | 2.74 | Low : | 1.3 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ NKTX ] has closed above the upper band by 2.9%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 30.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.19 - 2.2 | 2.2 - 2.21 |
| Low: | 2.02 - 2.03 | 2.03 - 2.04 |
| Close: | 2.16 - 2.18 | 2.18 - 2.19 |
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Thu, 04 Dec 2025
We Think Nkarta (NASDAQ:NKTX) Needs To Drive Business Growth Carefully - Yahoo Finance
Tue, 02 Dec 2025
Nkarta to Participate in Evercore Healthcare Conference - GlobeNewswire
Sat, 22 Nov 2025
Nkarta: Pushing Deeper And Deeper Into A Discount Vs. Their Holdings, For No Real Reason - Seeking Alpha
Tue, 11 Nov 2025
Nkarta (NKTX) Upgraded to Buy: Here's Why - MSN
Tue, 11 Nov 2025
Stifel lowers Nkarta stock price target to $11 from $12, keeps Buy rating - Investing.com
Mon, 10 Nov 2025
Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 71 (M) |
| Shares Float | 56 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 85.5 (%) |
| Shares Short | 10,850 (K) |
| Shares Short P.Month | 9,620 (K) |
| EPS | -1.38 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.76 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -15.2 % |
| Return on Equity (ttm) | -26.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.51 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -92 (M) |
| Levered Free Cash Flow | -58 (M) |
| PE Ratio | -1.58 |
| PEG Ratio | 0 |
| Price to Book value | 0.45 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.69 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|